Q-omics provides the consensus-scored TTC36 profile across patient tissues and cancer cell-line models. TTC36 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TTC36 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, TTC36 RNA expression shows 20,132 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KIRP, and THYM as cancer lineages where TTC36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC36 survival associations across molecular data types. TTC36 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC36 RNA expression–survival associations across cancer types. High TTC36 expression shows unfavorable associations in CESC, but favorable associations in BRCA, KIRP, UCS, LIHC and READ. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TTC36 RNA expression.
This table summarizes TTC36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTC36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC36 shows lower tumor expression in KIRP, KIRC, LIHC, KICH, CHOL and THCA. The KIRP box plot shows higher TTC36 RNA expression in normal versus tumor tissue (log2 FC = −2.912, t-test p < 0.001).
This table shows molecular features associated with TTC36 in patient tissues and cancer cell lines. In patient samples, TTC36 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC36 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
